Nascent Biotech, Inc.
NBIO · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $115 | $181 | $0 |
| Gross Profit | $0 | -$115 | -$181 | $0 |
| % Margin | – | – | -5,361,374.4% | – |
| R&D Expenses | $3 | $16 | $20 | $66 |
| G&A Expenses | $0 | $245 | $315 | $296 |
| SG&A Expenses | $248 | $245 | $315 | $298 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $0 | $115 | $181 | $0 |
| Operating Expenses | $251 | $376 | $516 | $364 |
| Operating Income | -$251 | -$376 | -$516 | -$364 |
| % Margin | – | – | -15,284,360.2% | – |
| Other Income/Exp. Net | -$1 | -$2 | $3 | $159 |
| Pre-Tax Income | -$252 | -$377 | -$513 | -$205 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$252 | -$377 | -$513 | -$205 |
| % Margin | – | – | -15,195,497.6% | – |
| EPS | -0.002 | -0.002 | -0.003 | -0.001 |
| % Growth | 31.8% | 26.7% | -150% | – |
| EPS Diluted | -0.002 | -0.002 | -0.003 | -0.001 |
| Weighted Avg Shares Out | 172,202 | 170,657 | 170,594 | 167,244 |
| Weighted Avg Shares Out Dil | 172,202 | 170,657 | 170,594 | 167,244 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $4 |
| Interest Expense | $1 | $2 | -$3 | $25 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$251 | -$375 | -$513 | -$364 |
| % Margin | – | – | -15,182,908.8% | – |